|
Aug 24
|
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
|
|
Aug 24
|
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year
|
|
Aug 21
|
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
|
|
Aug 11
|
3 Things About Recursion Pharmaceuticals That Smart Investors Know
|
|
Aug 8
|
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 8
|
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
|
|
Aug 8
|
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
|
|
Jul 12
|
AI Drug Discovery Firm Recursion Surges Following $50 Million Nvidia Investment
|
|
Jul 12
|
Recursion Catapults 78% On Nvidia Investment For AI In Drug Development
|
|
Jul 12
|
Rebel's Edge - July 12: $UPS, $LCID, $RXRX, and MLB Locks & Sleepers
|
|
Jul 12
|
Recursion Pharmaceuticals Stock Surges On Nvidia Investment
|
|
Jul 12
|
Why Shares of Recursion Pharmaceuticals Are Skyrocketing Wednesday
|
|
Jul 12
|
Recursion Stock Soars After Nvidia Invests $50 Million for AI Drug Discovery
|
|
Jul 12
|
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
|
|
May 2
|
Recursion to Participate in Upcoming Investor Conferences
|